These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8221671

  • 21. New insights into p53 function from structural studies.
    Arrowsmith CH, Morin P.
    Oncogene; 1996 Apr 04; 12(7):1379-85. PubMed ID: 8622853
    [Abstract] [Full Text] [Related]

  • 22. Definition of a consensus binding site for p53.
    el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B.
    Nat Genet; 1992 Apr 04; 1(1):45-9. PubMed ID: 1301998
    [Abstract] [Full Text] [Related]

  • 23. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding.
    Cesková P, Chichger H, Wallace M, Vojtesek B, Hupp TR.
    J Mol Biol; 2006 Mar 24; 357(2):442-56. PubMed ID: 16438982
    [Abstract] [Full Text] [Related]

  • 24. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D, Ano Bom AP, Lima LM, Quesado PA, Oyama MF, de Moura Gallo CV, Cordeiro Y, Silva JL.
    Biochemistry; 2009 Jul 07; 48(26):6126-35. PubMed ID: 19505151
    [Abstract] [Full Text] [Related]

  • 25. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL.
    Oncogene; 2001 Jul 27; 20(33):4441-9. PubMed ID: 11494139
    [Abstract] [Full Text] [Related]

  • 26. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV, Das GC.
    Oncogene; 1996 Jul 18; 13(2):323-32. PubMed ID: 8710371
    [Abstract] [Full Text] [Related]

  • 27. SV40 T antigen abrogates p53-mediated transcriptional activity.
    Jiang D, Srinivasan A, Lozano G, Robbins PD.
    Oncogene; 1993 Oct 18; 8(10):2805-12. PubMed ID: 8378089
    [Abstract] [Full Text] [Related]

  • 28. Disruption of LT-antigen/p53 complex by heat treatment correlates with inhibition of DNA synthesis during transforming infection with SV40.
    Khandjian EW, Rose TM.
    Biochem Cell Biol; 2000 Oct 18; 78(4):437-45. PubMed ID: 11012082
    [Abstract] [Full Text] [Related]

  • 29. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V, Muller P, Brozkova K, Vojtesek B.
    Biochem Biophys Res Commun; 2006 Dec 15; 351(2):499-506. PubMed ID: 17070499
    [Abstract] [Full Text] [Related]

  • 30. The role of tetramerization in p53 function.
    Chène P.
    Oncogene; 2001 May 10; 20(21):2611-7. PubMed ID: 11420672
    [Abstract] [Full Text] [Related]

  • 31. Phosphorylation by DNAPK inhibits the DNA-binding function of p53/T antigen complex in vitro.
    Sheppard HM, Liu X.
    Anticancer Res; 1999 May 10; 19(3A):2079-83. PubMed ID: 10470151
    [Abstract] [Full Text] [Related]

  • 32. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA, Millhauser GL.
    Biopolymers; 1999 Mar 10; 49(3):215-24. PubMed ID: 9990839
    [Abstract] [Full Text] [Related]

  • 33. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53.
    Hall AR, Milner J.
    Oncogene; 1995 Feb 02; 10(3):561-7. PubMed ID: 7845681
    [Abstract] [Full Text] [Related]

  • 34. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress.
    Jiang M, Axe T, Holgate R, Rubbi CP, Okorokov AL, Mee T, Milner J.
    Oncogene; 2001 Sep 06; 20(39):5449-58. PubMed ID: 11571642
    [Abstract] [Full Text] [Related]

  • 35. Tumor suppressor protein p53 binds preferentially to supercoiled DNA.
    Palecek E, Vlk D, Stanková V, Brázda V, Vojtesek B, Hupp TR, Schaper A, Jovin TM.
    Oncogene; 1997 Oct 06; 15(18):2201-9. PubMed ID: 9393978
    [Abstract] [Full Text] [Related]

  • 36. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb.
    Simons A, Melamed-Bessudo C, Wolkowicz R, Sperling J, Sperling R, Eisenbach L, Rotter V.
    Oncogene; 1997 Jan 16; 14(2):145-55. PubMed ID: 9010216
    [Abstract] [Full Text] [Related]

  • 37. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL.
    Mol Cancer; 2006 Oct 20; 5():47. PubMed ID: 17054774
    [Abstract] [Full Text] [Related]

  • 38. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.
    Kim E, Albrechtsen N, Deppert W.
    Oncogene; 1997 Aug 14; 15(7):857-69. PubMed ID: 9266973
    [Abstract] [Full Text] [Related]

  • 39. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
    Stros M, Muselíková-Polanská E, Pospísilová S, Strauss F.
    Biochemistry; 2004 Jun 08; 43(22):7215-25. PubMed ID: 15170359
    [Abstract] [Full Text] [Related]

  • 40. Influence of magnesium ion on the binding of p53 DNA-binding domain to DNA-response elements.
    Xue Y, Wang S, Feng X.
    J Biochem; 2009 Jul 08; 146(1):77-85. PubMed ID: 19297420
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.